Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy
- PMID: 26302803
- DOI: 10.2174/1389450116666150825113035
Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy
Abstract
Cholangiocarcinoma (CCA) is a heterogeneous group of dysplastic disorders affecting the biliary epithelium. It is the second most common primary liver tumor which accounts for around 3% of all gastrointestinal cancers. CCA is very deadly due to its aggressiveness, late diagnosis and high chemoresistance. The incidence is increasing worldwide and the therapeutic options are very limited. Radiotherapy, chemotherapy, surgery and/or liver transplantation may be indicated in patients who meet certain criteria, but chances of success are low. There is therefore increasing interest in understanding the molecular mechanisms involved in the pathogenesis of this cancer type and in identifying new targets for therapy. Current strategies are based on targeting key signaling pathways involved in proliferation, survival, apoptosis and migration. In this review, the most relevant molecular mechanisms involved in the pathogenesis of CCA are discussed and the main preclinical and clinical studies are highlighted. Moreover, future directions in basic and clinical research are indicated.
Keywords: Biliary epithelium; cancer; cholangiocarcinoma; molecular mechanisms; pathogenesis; stroma; therapy.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.Liver Int. 2019 May;39 Suppl 1:43-62. doi: 10.1111/liv.14102. Liver Int. 2019. PMID: 30903728 Review.
-
Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):349-356. doi: 10.1080/17474124.2017.1292127. Epub 2017 Feb 13. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28162004
-
Cholangiocarcinoma: molecular pathways and therapeutic opportunities.Semin Liver Dis. 2014 Nov;34(4):456-64. doi: 10.1055/s-0034-1394144. Epub 2014 Nov 4. Semin Liver Dis. 2014. PMID: 25369307 Free PMC article. Review.
-
Emerging pathways for precision medicine in management of cholangiocarcinoma.Surg Oncol. 2020 Dec;35:47-55. doi: 10.1016/j.suronc.2020.08.008. Epub 2020 Aug 12. Surg Oncol. 2020. PMID: 32827952 Review.
-
The molecular pathogenesis of cholangiocarcinoma.Semin Liver Dis. 2004 May;24(2):127-37. doi: 10.1055/s-2004-828890. Semin Liver Dis. 2004. PMID: 15192786 Review.
Cited by
-
Apoptosis-Inducing Factor, Mitochondrion-Associated 3 (AIFM3) Protein Level in the Sera as a Prognostic Marker of Cholangiocarcinoma Patients.Biomolecules. 2020 Jul 10;10(7):1021. doi: 10.3390/biom10071021. Biomolecules. 2020. PMID: 32664187 Free PMC article.
-
SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.Cancer Med. 2019 May;8(5):2380-2391. doi: 10.1002/cam4.2089. Epub 2019 Apr 16. Cancer Med. 2019. PMID: 30993888 Free PMC article.
-
Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.Int J Biol Sci. 2018 May 22;14(8):920-929. doi: 10.7150/ijbs.24622. eCollection 2018. Int J Biol Sci. 2018. PMID: 29989102 Free PMC article. Review.
-
Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.In Vivo. 2022 May-Jun;36(3):1168-1177. doi: 10.21873/invivo.12816. In Vivo. 2022. PMID: 35478117 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical